Expert consensus on the diagnosis and treatment of retreatment pulmonary tuberculosis

doi:10.3969/j.issn.1000-6621.2021.12.002

Abstract

Abstract:

Retreatment pulmonary tuberculosis is an important part of the national tuberculosis control plan, and it is also a difficult point of tuberculosis control in China. The situation of patients with retreatment pulmonary tuberculosis is complex, and the previous treatment regimen is now outdated, and the classification and diagnosis of retreatment pulmonary tuberculosis should be reassessed. Therefore, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Beijing Chest Hospital, Capital Medical University, Chinese Antituberculosis Association, and Editorial Board of Chinese Journal of Antituberculosis organized domestic experts to repeatedly discuss the classification, diagnosis and treatment of retreatment pulmonary tuberculosis and then formed the “Expert consensus on the diagnosis and treatment of retreatment pulmonary tuberculosis” to standardize the diagnosis and treatment of retreatment pulmonary tuberculosis in China and improve the treatment effect.

Key words: Tuberculosis,pulmonary, Retreatment, Diagnosis, Clinical protocols, Consensus development conferences as topic

Shanghai Clinical Research Center for Infectious Disease (Tuberculosis)/Shanghai Pulmonary Hospital, Tongji University School of Medicine, Beijing Chest Hospital , Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis . Expert consensus on the diagnosis and treatment of retreatment pulmonary tuberculosis[J]. Chinese Journal of Antituberculosis, 2021, 43(12): 1226-1238. doi: 10.3969/j.issn.1000-6621.2021.12.002

References 88

[1]	中华人民共和国国家卫生和计划生育委员会. WS 196—2017 结核病分类. 2017-11-09.
[2]	World Health Organization. Global tuberculosis report 2020. Geneva: World Health Organization, 2020.
[3]	卫生部疾病预防控制局, 卫生部医政司, 中国疾病预防控制中心. 中国结核病防治规划实施工作指南(2008年版). 北京: 中国协和医科大学出版社, 2009.
[4]	杨国儒, 张绍坤, 王国锋, 等. 对复治肺结核患者的规范化治疗和个体化治疗的几点思考. 中华结核和呼吸杂志, 2004, 27(2):78-79.
[5]	Kritski AL, Rodrigues de Jesus LS, Andrade MK, et al. Retreatment tuberculosis cases. Factors associated with drug resistance and adverse outcomes. Chest, 1997, 111(5):1162-1167. doi: 10.1378/chest.111.5.1162. doi: 10.1378/chest.111.5.1162 pmid: 9149564
[6]	Sevim T, Ataç G, Güngör G, et al. Treatment outcome of relapse and defaulter pulmonary tuberculosis patients. Int J Tuberc Lung Dis, 2002, 6(4):320-325. pmid: 11936741
[7]	Getnet F, Sileshi H, Seifu W, et al. Do retreatment tuberculosis patients need special treatment response follow-up beyond the standard regimen? Finding of five-year retrospective study in pastoralist setting. BMC Infect Dis, 2017, 17(1):762. doi: 10.1186/s12879-017-2882-y. doi: 10.1186/s12879-017-2882-y URL
[8]	范玉美, 肖和平, 梅建. 上海市首次复治肺结核患者的耐药性分析. 中华结核和呼吸杂志, 2006, 29(10):698-701.
[9]	全国肺结核短化协作组. 第二批肺结核短程化疗研究初报. 中华结核和呼吸系疾病杂志, 1984, 7(4):198-202.
[10]	中华人民共和国卫生部. 全国结核病耐药性基线调查报告(2007—2008年). 北京: 人民卫生出版社, 2010: 49.
[11]	朱莉贞, 高孟秋, 陈巍, 等. 复治肺结核化疗新方案与原复治方案的临床对照研究. 中国防痨杂志, 2012, 34(5):304-309.
[12]	邹级谦. 复治肺结核标准化疗方案述评. 结核病健康教育, 2009(1):8-11.
[13]	唐神结, 肖和平. 复治涂阳肺结核化疗方案刍议. 中国防痨杂志, 2006, 28(2):69-70.
[14]	肖和平. 重视复治肺结核化疗方案的制定. 中华结核和呼吸杂志, 2007, 30(6):401-402.
[15]	马艳, 高微微. 今非昔比:重视复治肺结核的合理施治. 中国防痨杂志, 2021, 43(4):313-317. doi: 10.3969/j.issn.1000-6621.2021.04.002. doi: 10.3969/j.issn.1000-6621.2021.04.002
[16]	Vega V, Rodríguez S, Van der Stuyft P, et al. Recurrent TB: a systematic review and meta-analysis of the incidence rates and the proportions of relapses and reinfections. Thorax, 2021, 76(5):494-502. doi: 10.1136/thoraxjnl-2020-215449. doi: 10.1136/thoraxjnl-2020-215449 URL
[17]	彭红, 虞浩, 姜洁, 等. 江苏省初治结核病复发流行病学特征及影响因素. 江苏预防医学, 2019, 30(4):355-359. doi: 10.13668/j.issn.1006-9070.2019.04.001. doi: 10.13668/j.issn.1006-9070.2019.04.001
[18]	邱玉冰, 许琳, 杨蕊, 等. 云南省成功治疗肺结核患者5年复发情况及影响因素研究. 预防医学, 2020, 32(6):559-562. doi: 10.19485/j.cnki.issn2096-5087.2020.06.005. doi: 10.19485/j.cnki.issn2096-5087.2020.06.005
[19]	Shen X, Yang C, Wu J, et al. Recurrent tuberculosis in an urban area in China: Relapse or exogenous reinfection? Tuberculosis(Edinb), 2017, 103:97-104. doi: 10.1016/j.tube.2017.01.007. doi: 10.1016/j.tube.2017.01.007
[20]	Liu Y, Zhang XX, Yu JJ, et al. Tuberculosis relapse is more common than reinfection in Beijing, China. Infect Dis(Lond), 2020, 52(12):858-865. doi: 10.1080/23744235.2020.1794027. doi: 10.1080/23744235.2020.1794027
[21]	Korenromp EL, Scano F, Williams BG, et al. Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampin-based treatment: an analytical review. Clin Infect Dis, 2003, 37(1):101-112. doi: 10.1086/375220. doi: 10.1086/375220 pmid: 12830415
[22]	Baker MA, Harries AD, Jeon CY, et al. The impact of diabetes on tuberculosis treatment outcomes: a systematic review. BMC Med, 2011, 9:81. doi: 10.1186/1741-7015-9-81. doi: 10.1186/1741-7015-9-81 URL
[23]	van der Heijden YF, Karim F, Chinappa T, et al. Older age at first tuberculosis diagnosis is associated with tuberculosis recurrence in HIV-negative persons. Int J Tuberc Lung Dis, 2018, 22(8):871-877. doi: 10.5588/ijtld.17.0766. doi: 10.5588/ijtld.17.0766 pmid: 29991395
[24]	Zhdanov V, Bilenko N, Mor Z. Risk Factors for Recurrent Tuberculosis among Successfully Treated Patients in Israel, 1999—2011. Isr Med Assoc J, 2017, 19(4):237-241.
[25]	Crofts JP, Andrews NJ, Barker RD, et al. Risk factors for recurrent tuberculosis in England and Wales, 1998—2005. Thorax, 2010, 65(4):310-314. doi: 10.1136/thx.2009.124677. doi: 10.1136/thx.2009.124677 pmid: 20388755
[26]	Rosser A, Marx FM, Pareek M. Recurrent tuberculosis in the pre-elimination era. Int J Tuberc Lung Dis, 2018, 22(2):139-150. doi: 10.5588/ijtld.17.0590. doi: 10.5588/ijtld.17.0590 pmid: 29506610
[27]	杜建, 韩喜琴, 舒薇, 等. 复治菌阳肺结核患者治疗成功后再次复发的危险因素分析. 中国防痨杂志, 2019, 41(6):624-631. doi: 10.3969/j.issn.1000-6621.2019.06.007. doi: 10.3969/j.issn.1000-6621.2019.06.007
[28]	王倪, 杜建, 马艳, 等. 涂阳肺结核患者治疗失败影响因素分析. 中国防痨杂志, 2016, 38(6):450-455. doi: 10.3969/j.issn.1000-6621.2016.06.006. doi: 10.3969/j.issn.1000-6621.2016.06.006
[29]	Liu Q, Wang D, Martinez L, et al. Mycobacterium tuberculosis Beijing genotype strains and unfavourable treatment outcomes: a systematic review and meta-analysis. Clin Microbiol Infect, 2020, 26(2):180-188. doi: 10.1016/j.cmi.2019.07.016. doi: 10.1016/j.cmi.2019.07.016 URL
[30]	Zhao Y, Xu S, Wang L, et al. National survey of drug-resis-tant tuberculosis in China. N Engl J Med, 2012, 366(23):2161-2170. doi: 10.1056/NEJMoa1108789. doi: 10.1056/NEJMoa1108789 URL
[31]	Xie Z, Wang T, Chen H, et al. Factors associated with diagnostic delay in recurrent TB. BMC Public Health, 2020, 20(1):1207. doi: 10.1186/s12889-020-09005-9. doi: 10.1186/s12889-020-09005-9 URL
[32]	Wilcke JT, Kok-Jensen A. Diagnostic strategy for pulmonary tuberculosis in a low-incidence country: results of chest X-ray and sputum cultured for Mycobacterium tuberculosis. Respir Med, 1997, 91(5):281-285. doi: 10.1016/s0954-6111(97)90031-7. doi: 10.1016/s0954-6111(97)90031-7 URL
[33]	Theron G, Venter R, Calligaro G, et al. Xpert MTB/RIF Results in Patients With Previous Tuberculosis: Can We Distinguish True From False Positive Results? Clin Infect Dis, 2016, 62(8):995-1001. doi: 10.1093/cid/civ1223. doi: 10.1093/cid/civ1223 pmid: 26908793
[34]	World Health Organization. Using the Xpert MTB/RIF assay to detect pulmonary and extrapulmonary tuberculosis and rifampicin resistance in adults and children. Geneva: World Health Organization, 2013.
[35]	Theron G, Venter R, Smith L, et al. False-Positive Xpert MTB/RIF Results in Retested Patients with Previous Tuberculosis: Frequency, Profile, and Prospective Clinical Outcomes. J Clin Microbiol, 2018, 56(3):e01696-17. doi: 10.1128/JCM.01696-17. doi: 10.1128/JCM.01696-17
[36]	Mishra H, Reeve BWP, Palmer Z, et al. Xpert MTB/RIF Ultra and Xpert MTB/RIF for diagnosis of tuberculosis in an HIV-endemic setting with a high burden of previous tuberculosis: a two-cohort diagnostic accuracy study. Lancet Respir Med, 2020, 8(4):368-382. doi: 10.1016/S2213-2600(19)30370-4. doi: 10.1016/S2213-2600(19)30370-4 URL
[37]	Saavedra B, Mambuque E, Nguenha D, et al. Performance of Xpert MTB/RIF Ultra for tuberculosis diagnosis in the context of passive and active case finding[J/OL]. Eur Respir J, 2021[2021-09-14]. doi: 10.1183/13993003.00257-2021. Online ahead of print. doi: 10.1183/13993003.00257-2021
[38]	Kim HJ, Yoon HI, Park KU, et al. The impact of previous tuberculosis history on T-SPOT.TB^® interferon-gamma release assay results. Int J Tuberc Lung Dis, 2011, 15(4):510-516. doi: 10.5588/ijtld.10.0520. doi: 10.5588/ijtld.10.0520 pmid: 21396211
[39]	Darboe F, Mbandi SK, Naidoo K, et al. Detection of Tuberculosis Recurrence, Diagnosis and Treatment Response by a Blood Transcriptomic Risk Signature in HIV-Infected Persons on Antiretroviral Therapy. Front Microbiol, 2019, 10:1441. doi: 10.3389/fmicb.2019.01441. doi: 10.3389/fmicb.2019.01441 URL
[40]	中华医学会放射学分会传染病放射学专业委员会. 肺结核影像学及分级诊断专家共识. 新发传染病电子杂志, 2018, 3(2):118-127. doi: 10.3877/j.issn.2096-2738.2018.02.017. doi: 10.3877/j.issn.2096-2738.2018.02.017
[41]	吕平欣, 周新华, 谢汝明, 等. 成人原发型肺结核的CT表现. 中华放射学杂志, 2004, 38(1):15-19.
[42]	王云玲, 邓佳敏, 赵丽萍, 等. 37例血行播散性肺结核的多层螺旋CT与胸片表现分析. 结核病与肺部健康杂志, 2015, 4(3):153-156. doi: 10.3969/j.issn.2095-3755.2015.03.002. doi: 10.3969/j.issn.2095-3755.2015.03.002
[43]	沙巍, 肖和平, 刘一典, 等. 复治菌阴肺结核161例诊断的临床分析. 中国防痨杂志, 2010, 32(7):412-413.
[44]	杨佳, 吕圣秀, 唐光孝, 等. 初治与复治耐多药肺结核患者的CT表现分析. 中国防痨杂志, 2020, 42(1):38-43. doi: 10.3969/j.issn.1000-6621.2020.01.010. doi: 10.3969/j.issn.1000-6621.2020.01.010
[45]	余卫业, 谭卫国, 陆普选. 耐药肺结核的分类、分型及影像学表现. 新发传染病电子杂志, 2019, 4(1):42-47. doi: 10.3877/j.issn.2096-2738.2019.01.010. doi: 10.3877/j.issn.2096-2738.2019.01.010
[46]	周新华. 肺结核的影像学诊断——从形态分析到分子影像诊断. 中国防痨杂志, 2014, 36(8):638-642. doi: 10.3969/j.issn.1000-6621.2014.08.004. doi: 10.3969/j.issn.1000-6621.2014.08.004
[47]	李利佳, 王迪, 刘倩颖, 等. 320层CT双入口灌注技术观察复治涂阳肺结核患者病灶灌注特点. 中国防痨杂志, 2016, 38(5):349-353. doi: 10.3969/j.issn.1000-6621.2016.05.005. doi: 10.3969/j.issn.1000-6621.2016.05.005
[48]	Lewinsohn DM, Leonard MK, LoBue PA, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clin Infect Dis, 2017, 64(2):111-115. doi: 10.1093/cid/ciw778. doi: 10.1093/cid/ciw778 pmid: 28052967
[49]	中华医学会结核病学分会临床检验专业委员会. 结核病病原学分子诊断专家共识. 中华结核和呼吸杂志, 2018, 41(9):688-695. doi: 10.3760/cma.j.issn.1001-0939.2018.09.008. doi: 10.3760/cma.j.issn.1001-0939.2018.09.008
[50]	《中国防痨杂志》编辑委员会, 中国医疗保健国际交流促进会结核病防治分会基础学组和临床学组. 结核分枝杆菌耐药性检测专家共识. 中国防痨杂志, 2019, 41(2):129-137. doi: 10.3969/j.issn.1000-6621.2019.02.003. doi: 10.3969/j.issn.1000-6621.2019.02.003
[51]	国家感染性疾病临床医学研究中心, 深圳市第三人民医院, 《中国防痨杂志》编辑委员会. 肺结核活动性判断规范及临床应用专家共识. 中国防痨杂志, 2020, 42(4):301-307. doi: 10.3969/j.issn.1000-6621.2020.04.001. doi: 10.3969/j.issn.1000-6621.2020.04.001
[52]	中华人民共和国国家卫生和计划生育委员会. WS 288—2017 肺结核诊断. 2017-11-09.
[53]	胡品津, 谢灿茂. 内科疾病鉴别诊断学. 6版. 北京: 人民卫生出版社, 2016: 188-205.
[54]	中国防痨协会. 病原学检测阴性肺结核诊断流程(T/CHATA 008—2020). 2020-09-22.
[55]	王雪静, 戴元生, 曹继平, 等. 不同复治涂阳肺结核患者全程间歇短程化疗效果评价. 中华结核和呼吸杂志, 2001, 24(8):472-476. doi: 10.3760/j:issn:1001-0939.2001.08.009. doi: 10.3760/j:issn:1001-0939.2001.08.009
[56]	沙巍, 张青, 崔文玉, 等. 首次复治肺结核患者短程化疗新方案的临床研究. 中国防痨杂志, 2017, 39(1):39-45. doi: 10.3969/j.issn.1000-6621.2017.01.011. doi: 10.3969/j.issn.1000-6621.2017.01.011
[57]	万利亚, 赵丰曾, 池延花, 等. 世界银行贷款结核病控制项目实施情况分析与探讨. 中国防痨杂志, 1996, 18(3):103-108.
[58]	中华人民共和国国家卫生健康委员会办公厅. 国家卫生健康委办公厅关于印发中国结核病预防控制工作技术规范(2020年版)的通知. 国卫办疾控函〔2020〕279号. 2020-04-02.
[59]	杜建, 刘宇红, 李亮, 等. 复治肺结核患者采用不同化疗方案的效果评价. 中国防痨杂志, 2016, 38(10):850-857. doi: 10.3969/j.issn.1000-6621.2016.10.013. doi: 10.3969/j.issn.1000-6621.2016.10.013
[60]	World Health Organization. WHO Consolidated Guidelines on Tuberculosis, Module 4: Treatment-Drug-Resistant Tuberculosis Treatment. Geneva: World Health Organization, 2020.
[61]	中国防痨协会. 耐药结核病化学治疗指南(2019年简版). 中国防痨杂志, 2019, 41(10):1025-1073. doi: 10.3969/j.issn.1000-6621.2019.10.001. doi: 10.3969/j.issn.1000-6621.2019.10.001
[62]	戈启萍, 杜建, 舒薇, 等. 优化方案治疗复治药物敏感肺结核的疗效评价. 中国防痨杂志, 2021, 43(4):328-334. doi: 10.3969/j.issn.1000-6621.2021.04.006. doi: 10.3969/j.issn.1000-6621.2021.04.006
[63]	World Health Organization. Guideline: Nutritional Care and Support for Patients with Tuberculosis. Geneva: World Health Organization, 2013.
[64]	王玉红, 王智慧, 李晓倩, 等. 初治、复治肺结核患者细胞免疫功能与营养状况比较. 中国热带医学, 2019, 19(2):132-135. doi: 10.13604/j.cnki.46-1064/r.2019.02.08. doi: 10.13604/j.cnki.46-1064/r.2019.02.08
[65]	中华医学会结核病学分会重症专业委员会. 结核病营养治疗专家共识. 中华结核和呼吸杂志, 2020, 43(1):17-26. doi: 10.3760/cma.j.issn.1001-0939.2020.01.006. doi: 10.3760/cma.j.issn.1001-0939.2020.01.006
[66]	首都医科大学附属北京胸科医院, 中国防痨协会临床试验专业分会, 《中国防痨杂志》编辑委员会. 环丝氨酸治疗结核病的临床用药指南. 中国防痨杂志, 2020, 42(6):533-540. doi: 10.3969/j.issn.1000-6621.2020.06.001. doi: 10.3969/j.issn.1000-6621.2020.06.001
[67]	中华医学会结核病学分会, 利奈唑胺抗结核治疗专家共识编写组. 利奈唑胺抗结核治疗专家共识. 中华结核和呼吸杂志, 2018, 41(1):14-19. doi: 10.3760/cma.j.issn.1001-0939.2018.01.006. doi: 10.3760/cma.j.issn.1001-0939.2018.01.006
[68]	《中国防痨杂志》编辑委员会, 中国医疗保健国际交流促进会结核病防治分会全国耐药结核病协作组. 耐药结核病化疗过程中药品不良反应处理的专家共识. 中国防痨杂志, 2019, 41(6):591-603. doi: 10.3969/j.issn.1000-6621.2019.06.003. doi: 10.3969/j.issn.1000-6621.2019.06.003
[69]	中华医学会结核病学分会. 抗结核药物性肝损伤诊治指南(2019年版). 中华结核和呼吸杂志, 2019, 42(5):343-356. doi: 10.3760/cma.j.issn.1001-0939.2019.05.007. doi: 10.3760/cma.j.issn.1001-0939.2019.05.007
[70]	Oelemann MC, Diel R, Vatin V, et al. Assessment of an optimized mycobacterial interspersed repetitive-unit-variable-number tandem-repeat typing system combined with spoligotyping for population-based molecular epidemiology studies of tuberculosis. J Clin Microbiol, 2007, 45(3):691-697. doi: 10.1128/JCM.01393-06. doi: 10.1128/JCM.01393-06 pmid: 17192416
[71]	Bang D, Andersen AB, Thomsen VO, et al. Recurrent tuberculosis in Denmark: relapse vs. re-infection. Int J Tuberc Lung Dis, 2010, 14(4):447-453. pmid: 20202303
[72]	Dippenaar A, De Vos M, Marx FM, et al. Whole genome sequencing provides additional insights into recurrent tuberculosis classified as endogenous reactivation by IS6110 DNA fingerprinting. Infect Genet Evol, 2019, 75:103948. doi: 10.1016/j.meegid.2019.103948. doi: S1567-1348(19)30168-6 pmid: 31276801
[73]	Korhonen V, Smit PW, Haanperä M, et al. Whole genome analysis of Mycobacterium tuberculosis isolates from recurrent episodes of tuberculosis, Finland, 1995—2013. Clin Microbiol Infect, 2016, 22(6):549-554. doi: 10.1016/j.cmi.2016.03.014. doi: 10.1016/j.cmi.2016.03.014 URL
[74]	孙宇峰, 张明新, 隋文君, 等. γ-干扰素释放试验联合肿瘤标志物CA-125在活动性肺结核诊断中的应用. 中华医学杂志, 2019, 99(8):599-604. doi: 10.3760/cma.j.issn.0376-2491.2019.08.007. doi: 10.3760/cma.j.issn.0376-2491.2019.08.007
[75]	杨松, 严晓峰, 曾晓刚, 等. 结核抗体检测对活动性肺结核的诊断价值评价. 中国防痨杂志, 2018, 40(1):47-52. doi: 10.3969/j.issn.1000-6621.2018.01.012. doi: 10.3969/j.issn.1000-6621.2018.01.012
[76]	Blauenfeldt T, Villar-Hernández R, García-García E, et al. Diagnostic Accuracy of Interferon Gamma-Induced Protein 10 mRNA Release Assay for Tuberculosis. J Clin Microbiol, 2020, 58(10):e00848-20. doi: 10.1128/JCM.00848-20. doi: 10.1128/JCM.00848-20
[77]	Lee K, Chung W, Jung Y, et al. CXCR3 ligands as clinical markers for pulmonary tuberculosis. Int J Tuberc Lung Dis, 2015, 19(2):191-199. doi: 10.5588/ijtld.14.0525. doi: 10.5588/ijtld.14.0525 pmid: 25574918
[78]	Reichler MR, Hirsch C, Yuan Y, et al. Predictive value of TNF-α, IFN-γ, and IL-10 for tuberculosis among recently exposed contacts in the United States and Canada. BMC Infect Dis, 2020, 20(1):553. doi: 10.1186/s12879-020-05185-2. doi: 10.1186/s12879-020-05185-2 pmid: 32736606
[79]	Perumal R, Padayatchi N, Yende-Zuma N, et al. A Moxifloxacin-based Regimen for the Treatment of Recurrent, Drug-sensitive Pulmonary Tuberculosis: An Open-label, Randomi-zed, Controlled Trial. Clin Infect Dis, 2020, 70(1):90-98. doi: 10.1093/cid/ciz152. doi: 10.1093/cid/ciz152 URL
[80]	Nunn AJ, Phillips PPJ, Meredith SK, et al. A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis. N Engl J Med, 2019, 380(13):1201-1213. doi: 10.1056/NEJMoa1811867. doi: 10.1056/NEJMoa1811867 URL
[81]	Conradie F, Everitt D, Crook AM. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. Reply. N Engl J Med, 2020, 382(24):2377. doi: 10.1056/NEJMc2009939. doi: 10.1056/NEJMc2009939
[82]	Wang L, Wu J, Li J, et al. Host-mediated ubiquitination of a mycobacterial protein suppresses immunity. Nature, 2020, 577(7792):682-688. doi: 10.1038/s41586-019-1915-7. doi: 10.1038/s41586-019-1915-7 URL
[83]	Ge P, Lei Z, Yu Y, et al. M.Tuberculosis PknG manipulates host autophagy flux to promote pathogen intracellular survival. Autophagy, 2021: 1-19. doi: 10.1080/15548627.2021.1938912. doi: 10.1080/15548627.2021.1938912
[84]	Shariq M, Quadir N, Sharma N, et al. Mycobacterium tuberculosis RipA Dampens TLR4-Mediated Host Protective Response Using a Multi-Pronged Approach Involving Autophagy, Apoptosis, Metabolic Repurposing, and Immune Modulation. Front Immunol, 2021, 12:636644. doi: 10.3389/fimmu.2021.636644. doi: 10.3389/fimmu.2021.636644 pmid: 33746976
[85]	Forrellad MA, Blanco FC, Marrero Diaz de Villegas R, et al. Rv2577 of Mycobacterium tuberculosis Is a Virulence Factor With Dual Phosphatase and Phosphodiesterase Functions. Front Microbiol, 2020, 11:570794. doi: 10.3389/fmicb.2020.570794. doi: 10.3389/fmicb.2020.570794 URL
[86]	Zhang SY, Fu JY, Guo XY, et al. Improvement cues of lesion absorption using the adjuvant therapy of traditional Chinese medicine Qinbudan tablet for retreatment pulmonary tuberculosis with standard anti-tuberculosis regimen. Infect Dis Poverty, 2020, 9(1):50. doi: 10.1186/s40249-020-00660-z. doi: 10.1186/s40249-020-00660-z URL
[87]	邱磊, 张少言, 郭晓燕, 等. 化疗方案加芩部丹片治疗复治涂阳肺结核患者的临床价值. 中国防痨杂志, 2020, 42(2):108-114. doi: 10.3969/j.issn.1000-6621.2020.02.006. doi: 10.3969/j.issn.1000-6621.2020.02.006
[88]	马改霞, 田黎明, 王钰, 等. 中西医结合治疗耐多药肺结核的系统评价/Meta分析的再评价. 中国防痨杂志, 2020, 42(2):95-100. doi: 10.3969/j.issn.1000-6621.2020.02.004. doi: 10.3969/j.issn.1000-6621.2020.02.004